Global Burden of Disease
Psoriasis is a chronic, non-contagious, painful, and disabling disease for which there is no cure and with negative impact on patients’ quality of life (QoL). It can occur at any age and is most common in the age group 50–69.1
125 million people worldwide or 2-4 percent of the total population have psoriasis, according to the World Psoriasis Day consortium. More than 85% of patients receiving treatment use topical drugs (ref: Lebwohl, Mark In the clinic Psoriasis Annals of Internal Medicine 3. April 2018 and according to the National Psoriasis Foundation (NPF), itch is present in between 70 and 90 percent of psoriasis patients, and together with flaking and scaling, itching is the most burdensome symptom to patients. In addition, people living with psoriatic disease are at an elevated risk of developing other chronic and serious health conditions, including arthritis, cardiovascular diseases, metabolic syndrome, inflammatory bowel disease and depression.
The total cost of psoriasis in the US is estimated to be around $35.2 billion, with $12.2 billion in incremental medical costs.2
The number of people in the US market living with psoriasis is estimated to be around 7.5 million people.3
For many reasons, psoriasis can be psychologically devastating. Patients’ lives become especially difficult when psoriasis is present in highly visible areas of the skin such as the face and hands (ref: WHO Global Report on Psoriasis 2016)
Current treatment options include topicals, orals and biologics depending on severity and if PSA (Psoriatic Arthritis) is present. According to the NPF system (National Psoriasis Foundation) psoriasis is defined as Mild (<3% body surface area [BSA] covered), Moderate (3%-10% BSA), or Severe (>10% BSA).
Approximately 80% of patients with psoriasis can sufficiently be treated with topical therapies due to disease being localized skin issues and patients on systemic therapies may also use topicals for spot treatment.4
Treating with topicals may be used across the entire treatment severity spectrum – mild, moderate, and severe. Studies show that poor adherence has historically been a major problem in topical therapies resulting in suboptimal treatment effect.5
In the pursuit of developing topicals that have fast onset and high efficacy topicals have been compromised on tolerability, safety, or convenience of use in daily routines.
Addressing adherence in addition, to topical treatment efficacy and safety is a key unmet need in the plaque psoriasis market.
To address this unmet need, MC2 Therapeutics is applying its PAD™ Technology to incorporate all three essentials in one product solution for the benefit of patients living with plaque psoriasis.
Psoriasis Treatment guidelines:
For further information on selected treatment guidelines, please visit below links:
MC2 Therapeutics is a proud partner of the National Psoriasis Foundation (NPF) please visit their website below for more information on psoriasis:
- Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Study 2010: Results by Cause 1990–2010. Seattle: IHME; 2012
- Vanderpuye-Orgle J, Zhao Y, Lu J, Shrestha A, Sexton A, Seabury S, Lebwohl M. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015 Jun;72(6):961-7.e5
- Based on the 2003-2006 and 2009-2010 NHANES and U.S. Census Bureau’s Current Population Survey. NHANES=National Health and Nutrition Examination Surveys
- Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH. Topical therapies for the treatment of plaque psoriasis: Systematic review and network meta-analyses. Br J Dermatol. 2013;168(5):954-967
- Augustin M, Radtke MA. Quality of life in psoriasis patients. Expert Rev Pharmacoecon Outcomes Res. 2014;14(4):559-68